Immunomedics to Present at Jefferies 2017 Global Healthcare Conference
June 01 2017 - 8:00AM
Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or “the Company”)
today announced that Michael R. Garone, Vice President, Finance and
Chief Financial Officer, will present at Jefferies 2017 Global
Healthcare Conference at 8:00 a.m. Eastern Time on Thursday, June
8, 2017, in New York City. A live audio webcast of the presentation
will be available on the Investors section of the Company’s website
at www.immunomedics.com.
About ImmunomedicsImmunomedics
(the “Company”) is a clinical-stage biopharmaceutical company
developing monoclonal antibody-based products for the targeted
treatment of cancer, autoimmune disorders and other serious
diseases. Immunomedics’ most advanced product candidate is IMMU-132
(sacituzumab govitecan), an antibody-drug conjugate that has
received Breakthrough Therapy Designation from the FDA for the
treatment of patients with triple-negative breast cancer who have
failed at least two prior therapies for metastatic disease.
Immunomedics’ primary goal is to bring IMMU-132 to market for the
benefit of patients and the creation of shareholder value. For
additional information on the Company, please visit its website at
www.immunomedics.com. The information on its website does not,
however, form a part of this press release.
Cautionary note regarding
forward-looking statementsThis release, in addition to
historical information, may contain forward-looking statements made
pursuant to the Private Securities Litigation Reform Act of 1995.
Such statements, including statements regarding clinical trials
(including the funding therefor, anticipated patient enrollment,
trial outcomes, timing or associated costs), regulatory
applications and related timelines, out-licensing arrangements,
forecasts of future operating results, potential collaborations,
and capital raising activities, timing for bringing any product
candidate to market, involve significant risks and uncertainties
and actual results could differ materially from those expressed or
implied herein. Factors that could cause such differences include,
but are not limited to, the Company’s dependence on business
collaborations or availability of required financing from capital
markets, or other sources on acceptable terms, if at all, in order
to further develop our products and finance our operations, new
product development (including clinical trials outcome and
regulatory requirements/actions), the risk that we or any of our
collaborators may be unable to secure regulatory approval of and
market our drug candidates, risks associated with the outcome of
pending litigation and competitive risks to marketed products, and
the Company’s ability to repay its outstanding indebtedness, if and
when required, as well as the risks discussed in the Company’s
filings with the Securities and Exchange Commission. The
Company is not under any obligation, and the Company expressly
disclaims any obligation, to update or alter any forward-looking
statements, whether as a result of new information, future events
or otherwise.
For More Information:
Dr. Chau Cheng
Senior Director, Investor Relations & Corporate Secretary
(973) 605-8200, extension 123
ccheng@immunomedics.com
Media/Investor Contact:
Dan Zacchei / Jaimee Pavia
Sloane & Company
212-486-9500
Dzacchei@sloanepr.com
Jpavia@sloanepr.com
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From Aug 2024 to Sep 2024
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From Sep 2023 to Sep 2024